Literature DB >> 19858460

Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study.

R Savica1, B R Grossardt, J M Carlin, M Icen, J H Bower, J E Ahlskog, D M Maraganore, D P Steensma, W A Rocca.   

Abstract

OBJECTIVE: It has been suggested that anemia may be a risk factor for dementia, for restless legs syndrome, and for Parkinson disease (PD). Thus, we investigated the association of anemia with the subsequent risk of PD using a case-control study design.
METHODS: We used the medical records-linkage system of the Rochester Epidemiology Project to identify 196 subjects who developed PD in Olmsted County, Minnesota, from 1976 through 1995. Each incident case was matched by age (+/-1 year) and sex to a general population control. We reviewed the complete medical records of cases and controls in the system to detect anemia defined using the World Health Organization criteria.
RESULTS: Anemia was more common in the history of cases than of controls (odds ratio 2.00, 95% confidence interval 1.31-3.06, p = 0.001). The association remained significant after adjustment for cigarette smoking, exposure to pesticides, or hysterectomy (in women). The association was not significantly different between men and women, or between PD patients with or without rest tremor. Analyses stratified by time of onset of anemia showed a greater association for anemia that started 20 to 29 years before the onset of PD. Hemoglobin levels were slightly but consistently lower in cases than in controls across all ages.
CONCLUSIONS: Our results support an association between anemia experienced early in life and the later development of Parkinson disease. The interpretation of this association remains uncertain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858460      PMCID: PMC2769554          DOI: 10.1212/WNL.0b013e3181bd80c1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

1.  Abnormalities of the electron transport chain in idiopathic Parkinson's disease.

Authors:  W D Parker; S J Boyson; J K Parks
Journal:  Ann Neurol       Date:  1989-12       Impact factor: 10.422

2.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

3.  History of the Rochester Epidemiology Project.

Authors:  L J Melton
Journal:  Mayo Clin Proc       Date:  1996-03       Impact factor: 7.616

Review 4.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

Review 5.  The environment, epigenetics and amyloidogenesis.

Authors:  Jinfang Wu; Md Riyaz Basha; Nasser H Zawia
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

6.  Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia.

Authors:  Jack M Guralnik; Richard S Eisenstaedt; Luigi Ferrucci; Harvey G Klein; Richard C Woodman
Journal:  Blood       Date:  2004-07-06       Impact factor: 22.113

7.  Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease.

Authors:  H Yoshino; Y Nakagawa-Hattori; T Kondo; Y Mizuno
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1992

8.  Characterization of the active site iron in tyrosine hydroxylase. Redox states of the iron.

Authors:  A J Ramsey; P J Hillas; P F Fitzpatrick
Journal:  J Biol Chem       Date:  1996-10-04       Impact factor: 5.157

9.  Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease.

Authors:  R H Haas; F Nasirian; K Nakano; D Ward; M Pay; R Hill; C W Shults
Journal:  Ann Neurol       Date:  1995-06       Impact factor: 10.422

10.  Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.

Authors:  C H Schenck; S R Bundlie; M W Mahowald
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

View more
  36 in total

1.  Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal:  Horm Behav       Date:  2012-06-08       Impact factor: 3.587

2.  Sex-specific brain erythropoietin regulation of mouse metabolism and hypothalamic inflammation.

Authors:  Soumyadeep Dey; Zhenzhong Cui; Oksana Gavrilova; Xiaojie Zhang; Max Gassmann; Constance T Noguchi
Journal:  JCI Insight       Date:  2020-03-12

3.  Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice.

Authors:  Pavle Matak; Andrija Matak; Sarah Moustafa; Dipendra K Aryal; Eric J Benner; William Wetsel; Nancy C Andrews
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

4.  Genetic deletion of the GATA1-regulated protein α-synuclein reduces oxidative stress and nitric oxide synthase levels in mature erythrocytes.

Authors:  Raffaele Renella; Julia S Schlehe; Dennis J Selkoe; David A Williams; Matthew J LaVoie
Journal:  Am J Hematol       Date:  2014-07-21       Impact factor: 10.047

Review 5.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

6.  Subjects at risk of Parkinson's disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study.

Authors:  Makoto Hattori; Takashi Tsuboi; Katsunori Yokoi; Yasuhiro Tanaka; Maki Sato; Keisuke Suzuki; Yutaka Arahata; Akihiro Hori; Motoshi Kawashima; Akihiro Hirakawa; Yukihiko Washimi; Hirohisa Watanabe; Masahisa Katsuno
Journal:  J Neurol       Date:  2020-02-07       Impact factor: 4.849

7.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Authors:  David Devos; Caroline Moreau; Jean Christophe Devedjian; Jérome Kluza; Maud Petrault; Charlotte Laloux; Aurélie Jonneaux; Gilles Ryckewaert; Guillaume Garçon; Nathalie Rouaix; Alain Duhamel; Patrice Jissendi; Kathy Dujardin; Florent Auger; Laura Ravasi; Lucie Hopes; Guillaume Grolez; Wance Firdaus; Bernard Sablonnière; Isabelle Strubi-Vuillaume; Noel Zahr; Alain Destée; Jean-Christophe Corvol; Dominik Pöltl; Marcel Leist; Christian Rose; Luc Defebvre; Philippe Marchetti; Z Ioav Cabantchik; Régis Bordet
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

8.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

9.  Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk.

Authors:  Paola Costa-Mallen; Cyrus P Zabetian; Pinky Agarwal; Shu-Ching Hu; Dora Yearout; Ali Samii; James B Leverenz; John W Roberts; Harvey Checkoway
Journal:  Parkinsonism Relat Disord       Date:  2015-07-10       Impact factor: 4.891

10.  Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.

Authors:  Joseph J Locascio; Shirley Eberly; Zhixiang Liao; Ganqiang Liu; Ashley N Hoesing; Karen Duong; Ana Trisini-Lipsanopoulos; Kaltra Dhima; Albert Y Hung; Alice W Flaherty; Michael A Schwarzschild; Michael T Hayes; Anne-Marie Wills; U Shivraj Sohur; Nicte I Mejia; Dennis J Selkoe; David Oakes; Ira Shoulson; Xianjun Dong; Ken Marek; Bin Zheng; Adrian Ivinson; Bradley T Hyman; John H Growdon; Lewis R Sudarsky; Michael G Schlossmacher; Bernard Ravina; Clemens R Scherzer
Journal:  Brain       Date:  2015-07-28       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.